Cannabis for Hot Flashes
What the evidence actually says about using cannabis to manage menopausal vasomotor symptoms — and what it doesn't.
A lot of people report cannabis helps them sleep through night sweats or feel less bothered by hot flashes. That's plausible — cannabis is genuinely useful for sleep and anxiety in some people. But there are zero randomized controlled trials showing cannabis reduces the frequency or intensity of hot flashes themselves. Survey data shows menopausal women are using it anyway, often instead of hormone therapy. That's a real signal, but it's not evidence of efficacy. Proceed with modest expectations.
Plain-language summary
Hot flashes and night sweats are the classic vasomotor symptoms of perimenopause and menopause. They're driven by changes in how the brain's thermoregulatory center responds to shifting estrogen levels, mediated in part by KNDy neurons in the hypothalamus [1].
Cannabis is popular among menopausal women. A 2020 survey of North American women found that over a quarter of respondents had used cannabis to manage menopause symptoms, and most said it helped [2]. A larger 2024 survey published in Menopause found similar patterns [3].
But popularity is not proof. There are no randomized controlled trials showing that THC, CBD, or whole-plant cannabis reduces hot flash frequency or severity No data. What cannabis may do is make hot flashes less bothersome by improving sleep, reducing anxiety, or blunting the emotional response — an indirect effect, not a physiological fix.
This article is not medical advice. Talk to a clinician familiar with both menopause and cannabis before making decisions, especially if you have cardiovascular risk factors, a history of hormone-sensitive cancer, or take other medications.
What probably works (for hot flashes specifically)
Nothing about cannabis has been shown to reduce hot flashes in controlled trials No data.
This is worth stating plainly. Marketing copy for CBD menopause products often implies otherwise, but as of this writing there is no published RCT — with THC, CBD, or a combination — demonstrating a reduction in the frequency, duration, or intensity of vasomotor symptoms. If a product page tells you otherwise, ask for the citation.
What might work (indirect effects)
Cannabis has better-supported effects on symptoms that co-occur with hot flashes:
- Sleep disruption from night sweats. Low-to-moderate doses of THC can reduce sleep-onset latency in some people, though tolerance builds quickly and long-term use may worsen sleep architecture [4] Weak / limited. CBD's effects on sleep are mixed and dose-dependent [5] Weak / limited.
- Anxiety and mood symptoms. CBD shows modest anxiolytic effects at certain doses in controlled studies, though studies specific to menopausal women are lacking [6] Weak / limited.
- Perceived bother of symptoms. The 2020 and 2024 survey studies suggest women find cannabis helpful for the overall menopause experience, which may reflect these indirect effects rather than direct action on hot flashes [2][3] Weak / limited.
In other words: cannabis may help you cope with hot flashes without actually making them happen less.
What doesn't work / weak or absent evidence
- CBD isolate for hot flash frequency. No RCT evidence No data. Widely marketed for menopause; claims outrun data.
- Topical CBD for hot flashes. Biologically implausible for a centrally-mediated thermoregulatory symptom, and no clinical evidence No data.
- "Balancing hormones" with cannabis. A common marketing claim. Cannabinoids interact with the endocrine system in complex ways [7], but there is no evidence they restore or rebalance estrogen in a way that treats menopause No data. Treat this as folklore.
- Specific strains or terpene profiles targeting menopause. No controlled evidence. The "indica vs. sativa" framing does not predict clinical effects Disputed.
What we don't know
Almost everything, honestly. We don't know:
- Whether any cannabinoid, at any dose, affects the hypothalamic KNDy circuitry that generates hot flashes.
- Whether long-term cannabis use in perimenopause alters symptom trajectory.
- How cannabis interacts with hormone therapy (HRT) or with SSRIs/SNRIs prescribed for hot flashes.
- Whether there are cannabinoid–menopause interactions specific to bone density, cardiovascular risk, or cognition during the menopausal transition.
The research pipeline is thin. The 2023 NAMS (now Menopause Society) position statement on nonhormone therapy for vasomotor symptoms did not recommend cannabis, citing insufficient evidence [8].
Comparison with standard treatments
Menopausal hormone therapy (MHT/HRT) remains the most effective treatment for hot flashes, typically reducing frequency by 75% or more in trials [8][9] Strong evidence. For women without contraindications, it is first-line.
Non-hormonal prescription options with evidence for hot flashes include:
- Fezolinetant (a neurokinin-3 receptor antagonist) — FDA-approved 2023, targets the KNDy pathway directly [10] Strong evidence.
- SSRIs/SNRIs such as paroxetine (low-dose paroxetine is FDA-approved for vasomotor symptoms) and venlafaxine [8] Strong evidence.
- Gabapentin and oxybutynin, with moderate evidence [8] Strong evidence.
Cannabis has not been compared head-to-head with any of these. Someone choosing cannabis over evidence-based options for hot flashes specifically is trading a known effective treatment for an unknown one. Using cannabis alongside standard treatment for sleep or anxiety is a different, more defensible calculation — but coordinate with your prescriber because of drug interactions (see below).
Risks and interactions
- Cardiovascular. Menopause increases cardiovascular risk. THC transiently raises heart rate and blood pressure; smoked cannabis carries additional cardiopulmonary risk [11] Strong evidence. Discuss with your clinician if you have hypertension, arrhythmia, or coronary disease.
- Drug interactions. CBD inhibits CYP3A4 and CYP2C19 and can raise levels of many medications, including some SSRIs, benzodiazepines, and warfarin [12] Strong evidence. THC and CBD can both interact with tamoxifen metabolism — relevant if you have a history of hormone-sensitive breast cancer [12] Weak / limited.
- Bone health. Menopause accelerates bone loss. Chronic heavy cannabis use has been associated with lower bone mineral density in some studies [13] Weak / limited.
- Cognition and mood. Perimenopause already involves brain fog and mood shifts for many people. Regular THC use can worsen short-term memory and, in some users, anxiety Strong evidence.
- Dependence. Cannabis use disorder affects roughly 9–10% of adult users, with higher rates for daily users [14] Strong evidence.
Not medical advice. This article summarizes published evidence for educational purposes. Individual decisions about menopause management should involve a clinician who knows your history.
Sources
- Peer-reviewed Rance NE, Dacks PA, Mittelman-Smith MA, et al. (2013). Modulation of body temperature and LH secretion by hypothalamic KNDy neurons: a novel hypothesis on the mechanism of hot flushes. Frontiers in Neuroendocrinology, 34(3), 211-227.
- Peer-reviewed Dahlgren MK, El-Abboud C, Lambros AM, et al. (2022). A survey of medical cannabis use during perimenopause and postmenopause. Menopause, 29(9), 1028-1036.
- Peer-reviewed Han L, Yang Y, Ma M, et al. (2024). Cannabis use among midlife women for menopause-related symptoms. Menopause.
- Peer-reviewed Babson KA, Sottile J, Morabito D (2017). Cannabis, cannabinoids, and sleep: a review of the literature. Current Psychiatry Reports, 19(4), 23.
- Peer-reviewed Kisiolek JN, Flores VA, Ramani A, et al. (2023). Eight weeks of daily cannabidiol supplementation improves sleep quality and immune cell cytotoxicity. Nutrients, 15(19), 4173.
- Peer-reviewed Bergamaschi MM, Queiroz RH, Chagas MH, et al. (2011). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology, 36(6), 1219-1226.
- Peer-reviewed Brents LK (2016). Marijuana, the endocannabinoid system and the female reproductive system. Yale Journal of Biology and Medicine, 89(2), 175-191.
- Peer-reviewed The Menopause Society (2023). The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause, 30(6), 573-590.
- Peer-reviewed MacLennan AH, Broadbent JL, Lester S, Moore V (2004). Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database of Systematic Reviews, (4), CD002978.
- Peer-reviewed Lederman S, Ottery FD, Cano A, et al. (2023). Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet, 401(10382), 1091-1102.
- Peer-reviewed Page RL, Allen LA, Kloner RA, et al. (2020). Medical marijuana, recreational cannabis, and cardiovascular health: A scientific statement from the American Heart Association. Circulation, 142(10), e131-e152.
- Peer-reviewed Brown JD, Winterstein AG (2019). Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. Journal of Clinical Medicine, 8(7), 989.
- Peer-reviewed Sophocleous A, Robertson R, Ferreira NB, et al. (2017). Heavy cannabis use is associated with low bone mineral density and an increased risk of fractures. American Journal of Medicine, 130(2), 214-221.
- Peer-reviewed Hasin DS, Saha TD, Kerridge BT, et al. (2015). Prevalence of marijuana use disorders in the United States between 2001-2002 and 2012-2013. JAMA Psychiatry, 72(12), 1235-1242.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.